Rezolute to Initiate a Pivotal Phase III Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Rezolute, Inc. plans to initiate sunRIZE, a pivotal Phase II clinical study of RZ358, in Europe and other geographies outside the US in Q4 2023.